CGEM - Cullinan Oncology LLC - Stock & Dividends

Cullinan Oncology LLC, a biopharmaceutical company, is dedicated to developing innovative oncology therapies to improve the lives of cancer patients in the United States.

The company's lead program, CLN-619, is a monoclonal antibody currently in Phase I clinical trial, aiming to treat solid tumors. This promising treatment has the potential to revolutionize cancer care by targeting specific tumor cells, reducing harm to healthy cells, and improving patient outcomes.

In addition to CLN-619, Cullinan Oncology's development portfolio includes a range of cutting-edge therapies. CLN-049, a humanized bispecific antibody, is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndrome. CLN-418, a human bispecific immune activator, is in Phase 1 clinical trial for the treatment of multiple solid tumors, leveraging the body's immune system to combat cancer. Zipalertinib, a bioavailable small-molecule, is being developed to treat patients with non-small cell lung cancer, offering a new hope for those affected by this devastating disease.

The company's pipeline also includes CLN-617, a fusion protein for the treatment of solid tumors, and CLN-978, a T cell engaging antibody for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. These innovative therapies demonstrate Cullinan Oncology's commitment to pushing the boundaries of cancer treatment and improving patient outcomes.

Cullinan Oncology has established strategic partnerships to accelerate its research and development efforts. The company has license and collaboration agreements with Adimab, LLC, to discover and optimize antibodies, and with Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418. Additionally, Cullinan Oncology has a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib.

Headquartered in Cambridge, Massachusetts, Cullinan Oncology LLC was founded in 2016 and has since become a leader in the biopharmaceutical industry. The company's dedication to innovation, collaboration, and patient-centricity has positioned it for success in the pursuit of life-changing cancer therapies.

For more information, please visit Cullinan Oncology's website at https://cullinantherapeutics.com.